MARKET

MYOV

MYOV

MYOVANT SCIENCES
NYSE

Real-time Quotes | Nasdaq Last Sale

24.23
+0.48
+2.02%
Closed 19:45 12/01 EST
OPEN
23.95
PREV CLOSE
23.75
HIGH
24.29
LOW
23.56
VOLUME
607.22K
TURNOVER
--
52 WEEK HIGH
24.34
52 WEEK LOW
5.98
MARKET CAP
2.20B
P/E (TTM)
-8.6329
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Attention Biotech Investors: Mark Your Calendar For December PDUFA Dates
The U.S. Food and Drug Administration's approval machinery churned out a lot of disappointments in November. Most of the negative verdicts were tied to difficulties the agency has had in inspecting facilities where investigational drugs are being manufactured, amid COVID-19-related restrictions.
Benzinga · 3d ago
Myovant Sciences to Present at Upcoming December Investor Conferences
BASEL, Switzerland, Nov. 23, 2020 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, invites investors and the general public to listen to webcasts at the following investor conferences: * Evercore ISI 3rd Annual HealthCONx Virtual Conference on December 1, 2020 at 4:45 p.m. Eastern time. Lynn Seely, M.D., chief executive officer of Myovant Sciences, Inc., and Frank Karbe, president and chief financial officer of Myovant Sciences, Inc., will participate in a webcast presentation. Management will also participate in virtual one-on-one investor meetings on December 1. * Piper Sandler 32nd Annual Virtual Healthcare Conference. A pre-recorded presentation by Dr. Seely will be available at 10 a.m. Eastern time today on the investor relations page of Myovant’s website, investors.myovant.com. Management will participate in virtual one-on-one investor meetings on December 3, 2020. The presentations will be accessible on the Events page under the Investors & Media section of the Myovant website at www.myovant.com.About Myovant Sciences Myovant Sciences aspires to redefine care for women and for men through purpose-driven science, empowering medicines, and transformative advocacy. Our lead product candidate, relugolix, is a once-daily, oral GnRH receptor antagonist. Relugolix monotherapy tablet (120 mg) is under regulatory review in the U.S. for men with advanced prostate cancer. Relugolix combination tablet (relugolix 40 mg, estradiol 1.0 mg, and norethindrone acetate 0.5 mg) is under regulatory review in Europe and the U.S. for women with uterine fibroids and is under development for women with endometriosis. We are also developing MVT-602, an oligopeptide kisspeptin-1 receptor agonist, which has completed a Phase 2a study for female infertility as part of assisted reproduction. Sumitovant Biopharma, Ltd., a wholly owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd., is our majority shareholder. For more information, please visit our website at www.myovant.com. Follow @Myovant on Twitter and LinkedIn.Investor Contact: Ryan Crowe Vice President, Investor Relations Myovant Sciences, Inc. investors@myovant.comMedia Contact: Albert Liao Director, Corporate Communications Myovant Sciences, Inc. media@myovant.com
GlobeNewswire · 11/23 12:00
Breakeven On The Horizon For Myovant Sciences Ltd. (NYSE:MYOV)
We feel now is a pretty good time to analyse Myovant Sciences Ltd.'s (NYSE:MYOV) business as it appears the company...
Simply Wall St. · 11/18 06:37
Myovant Sciences Announces New Employment Inducement Grants Under NYSE Rule 303A.08
Myovant Sciences Announces New Employment Inducement Grants Under NYSE Rule 303A.08 BASEL, Switzerland, Nov. 17, 2020 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining
Benzinga · 11/17 13:33
Urovant Sciences, Zomedica leads healthcare gainers; Cassava Sciences, Allied Healthcare Products among major losers
Gainers: Urovant Sciences (UROV) +94%, Zomedica (ZOM) +35%, Ovid Therapeutics (OVID) +16%, Fulgent Genetics (FLGT) +12%, Myovant Sciences (MYOV) +11%.Losers: Cassava Sciences (SAVA) -26%, Allied Healthcare Products (AHPI) -24%, Biocept (BIOC) -19%, Zhongchao (ZCMD) -14%, IMAC Holdings (IMAC) -14%.
Seekingalpha · 11/13 16:03
The Daily Biotech Pulse: AstraZeneca's Cancer Drug Flunks COVID-19 Studies, Five Prime On a Roll, Morphosys, Xencor, Incyte Strike Cancer Deal
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Nov. 11)
Benzinga · 11/12 12:44
Recap: Myovant Sciences Q2 Earnings
Shares of Myovant Sciences (NYSE:MYOV) rose 0.2% in pre-market trading after the company reported Q2 results.Quarterly Results Earnings per share rose 5.06% over the past year to ($0.75), which missed the estimate of ($0.73).Revenue of $0 unchanged by 0.00% year over year, which missed the estimate of $290,000.Looking Ahead Earnings guidance hasn't been issued by the company for now.Myovant Sciences hasn't issued any revenue guidance for the time being.How To Listen To The Conference Call Date: Nov 12, 2020View more earnings on MYOVTime: 08:30 AMET Webcast URL: https://edge.media-server.com/mmc/p/mkxeraxuTechnicals Company's 52-week high was at $23.04Company's 52-week low was at $5.39Price action over last quarter: down 0.84%Company Profile Myovant Sciences Ltd is a healthcare company focused on redefining care for women and for men. The company's lead product candidate is relugolix, a once-daily, oral GnRH receptor antagonist. It has three late-stage clinical programs for relugolix in uterine fibroids, endometriosis, and prostate cancer. The company is also developing MVT-602, an oligopeptide kisspeptin-1 receptor agonist, that has completed a Phase 2a study for the treatment of female infertility as part of assisted reproduction.See more from Benzinga * Click here for options trades from Benzinga * Earnings Scheduled For November 12, 2020(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga · 11/12 12:39
Myovant Sciences Q2 EPS $(0.75) Misses $(0.73) Estimate
Myovant Sciences (NYSE:MYOV) reported quarterly losses of $(0.75) per share which missed the analyst consensus estimate of $(0.73) by 2.74 percent. This is a 5.06 percent increase over losses of $(0.79) per share from
Benzinga · 11/12 12:11
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of MYOV. Analyze the recent business situations of MYOVANT SCIENCES through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 8 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average MYOV stock price target is 30.86 with a high estimate of 55.00 and a low estimate of 20.00.
EPS
Institutional Holdings
Institutions: 145
Institutional Holdings: 44.56M
% Owned: 49.19%
Shares Outstanding: 90.59M
TypeInstitutionsShares
Increased
30
2.03M
New
44
-843.75K
Decreased
33
3.40M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-0.30%
Pharmaceuticals & Medical Research
+0.62%
Key Executives
Chairman/Director
Myrtle Potter
Chief Executive Officer/Director
Lynn Seely
Chief Financial Officer/Chief Accounting Officer
Frank Karbe
General Counsel/Secretary
Matthew Lang
Other/Director
Adele Gulfo
Other
Juan Camilo Arjona Ferreira
Lead Director/Independent Director
Kathleen Sebelius
Other
Kim Sablich
Director
Hiroshi Nomura
Independent Director
Terrie Curran
Independent Director
Mark Guinan
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About MYOV
Myovant Sciences Ltd, is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing therapies for the treatment women’s health and endocrine diseases. Its lead product candidate is Relugolix, which is an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone (GnRH) receptor antagonist that binds to and inhibits receptors in the anterior pituitary gland. Inhibition of GnRH receptors decreases the release of the gonadotropins, luteinizing hormone (LH), and follicle-stimulating hormone (FSH), thereby decreasing the down-stream production of estrogen and progesterone by the ovaries in women and testosterone by the testes in men. It is also advancing relugolix for the treatment of heavy menstrual bleeding associated with uterine fibroids, endometriosis-associated pain, and advanced prostate cancer. The Company is developing MVT-602, an oligopeptide kisspeptin agonist, for the treatment of female infertility.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Myovant Sciences Ltd stock information, including NYSE:MYOV real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MYOV stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading MYOV stock methods without spending real money on the virtual paper trading platform.